News | April 07, 2015

United Kingdom to Receive First Three Proton Beam Therapy Centers

First center will be operational in 2016, remaining two by 2017

UK, United Kingdom, proton beam therapy centers, Proton Partners International

April 7, 2015 — The United Kingdom is to get its first three proton beam therapy centers, marking a significant breakthrough in the provision of cancer treatment. Cardiff-based Proton Partners International Ltd is to open the treatment centers in Cardiff, London and Northumberland by 2017; the first - Cardiff - will be operational next year. The centers will be available for National Health Service (NHS) patients from England, Scotland and Wales, medically-insured private patients and self-paying patients.

Proton Partners International was formed following discussions between Prof. Sir Chris Evans, the leading life sciences entrepreneur, and leading U.K. life sciences and healthcare investors on addressing cancer treatment in the United Kingdom. Institutional and private investors have committed to almost £100m equity finance in the company.

Prof. Gordon McVie, senior consultant at the European Institute of Oncology, has been appointed chairman, and Prof. Karol Sikora has agreed to become chief medical adviser to the company, alongside a range of renowned cancer and healthcare experts.

McVie said: "This is an exciting and important development of the provision of cancer treatment in the U.K. As things stand, patients who can benefit from this treatment have to go abroad for treatment, often at great expense to the NHS. The creation of these centers will go a long way to ensuring the very best of treatment is available in the U.K."

Sikora said: "I was delighted to be approached by Sir Chris as there are only 40 proton beam therapy centers around the world and a pressing need for more. In the U.K. there are none. Given the aging population, there will be a significant rise in the number of cancer cases in the U.K., and therefore we should do what is necessary to provide the appropriate level and type of care."

Evans and his team at Arthurian Life Sciences, which manages the £100 million Wales Life Sciences Investment Fund established by the Welsh Government, are investing in the company through the fund.

In addition to state-of-the-art Proton Partners' treatment services, the Cardiff center will provide conventional radiotherapy, chemotherapy and supportive care. This could then be offered through other centers.

In the future, Proton Partners International intends to develop further proton therapy centers in Asia, the Middle East and Africa.

The government has announced that it will create two NHS proton beam therapy units, which will open in 2018.

For more information: www.nhs.uk

Related Content

News | Radiation Therapy | May 06, 2021
May 6, 2021 — Individuals living with severe...
The emergence of #therapeutic #radiopharmaceuticals and its adoption in #cancer care provide one more weapon in combating cancer

Getty Images

Feature | Radiation Oncology | May 04, 2021 | By Vinay Shivaprasad
The term nuclear medicine is associated with the diag
#prostatecancer During the first wave of the corona pandemic, 36 percent fewer men were diagnosed with prostate cancer in Sweden than in previous years.

Getty Images

News | Prostate Cancer | April 30, 2021
April 30, 2021 — During the first wave of the corona pandemic, 36 percent fewer men were diagnosed with prostate canc
A phase 1 clinical trial led by investigators at the University of Chicago Medicine testing the effects of stereotactic body radiotherapy for treating multiple metastases has determined that treatments used for single tumors can also be safely used for treating patients with multiple metastases.

Image courtesy of Accuray

News | Stereotactic Body Radiation Therapy (SBRT) | April 23, 2021
April 23, 2021 — A phase 1 clinical trial led by investigators at the...
A Norwegian study for the first time reveals benefit of the #PARP inhibitor #Olaparib in patients with early #breastcancer not harboring germline mutations

Getty Images

News | Radiation Therapy | April 22, 2021
April 22, 2021 — Targeted therapy in early stages of breas...
Varian announced it is collaborating with Google Cloud to build an advanced artificial intelligence (AI) based diagnostic platform to aid in the fight against cancer. Varian and Google Cloud AI embarked on a deployment journey, using Neural Architecture Search (NAS) technology via Google Cloud AI Platform, to create AI models for organ segmentation — a crucial and labor-intensive step in radiation oncology that can be a bottleneck in the cancer treatment clinical workflow.
News | Artificial Intelligence | April 08, 2021
April 8, 2021 — Varian announced it is collaborating with Google...
Brain tumors edged out by artificial intelligence: VBrain applies auto-contouring to the three most common types of brain tumors: brain metastasis, meningioma and acoustic neuroma.

Brain tumors edged out by artificial intelligence: VBrain applies auto-contouring to the three most common types of brain tumors: brain metastasis, meningioma and acoustic neuroma.

News | Artificial Intelligence | April 07, 2021
April 7, 2021 — Vysioneer, a leader in a...
The National Comprehensive Cancer Network® (NCCN®) and the American Cancer Society (ACS) are teaming up with leading health organizations across the country to endorse the safe resumption of cancer screening and treatment during the ongoing COVID-19 pandemic.
News | Radiation Therapy | March 31, 2021
March 31, 2021 — Doctors who oversee cancer clinics say that new patients are arriving for treatment with more advanc